DK0591280T3 - Anvendelse af tetrahydrocarbazolderivater som 5HT1-receptoragonister - Google Patents

Anvendelse af tetrahydrocarbazolderivater som 5HT1-receptoragonister

Info

Publication number
DK0591280T3
DK0591280T3 DK92912379T DK92912379T DK0591280T3 DK 0591280 T3 DK0591280 T3 DK 0591280T3 DK 92912379 T DK92912379 T DK 92912379T DK 92912379 T DK92912379 T DK 92912379T DK 0591280 T3 DK0591280 T3 DK 0591280T3
Authority
DK
Denmark
Prior art keywords
receptor agonists
tetrahydrocarbazole derivatives
tetrahydrocarbazole
derivatives
agonists
Prior art date
Application number
DK92912379T
Other languages
Danish (da)
English (en)
Inventor
Francis David King
Laramie Mary Gaster
Alberto Julio Kaumann
Rodney Christopher Young
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10697363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0591280(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DK0591280T3 publication Critical patent/DK0591280T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK92912379T 1991-06-26 1992-06-17 Anvendelse af tetrahydrocarbazolderivater som 5HT1-receptoragonister DK0591280T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919113802A GB9113802D0 (en) 1991-06-26 1991-06-26 Medicaments
PCT/GB1992/001082 WO1993000086A1 (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5ht1 receptor agonists

Publications (1)

Publication Number Publication Date
DK0591280T3 true DK0591280T3 (da) 1999-02-15

Family

ID=10697363

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92912379T DK0591280T3 (da) 1991-06-26 1992-06-17 Anvendelse af tetrahydrocarbazolderivater som 5HT1-receptoragonister

Country Status (35)

Country Link
US (2) US5464864A (de)
EP (1) EP0591280B1 (de)
JP (1) JP3261502B2 (de)
KR (1) KR100251571B1 (de)
CN (1) CN1034072C (de)
AP (1) AP344A (de)
AT (1) ATE170746T1 (de)
BR (2) BR9206237A (de)
CA (1) CA2113726C (de)
CZ (3) CZ282327B6 (de)
DE (2) DE69226953T2 (de)
DK (1) DK0591280T3 (de)
FI (1) FI103967B (de)
GB (1) GB9113802D0 (de)
HK (1) HK1014669A1 (de)
HU (1) HU218907B (de)
IE (1) IE922062A1 (de)
IL (4) IL117105A0 (de)
LU (1) LU90939I2 (de)
MA (1) MA22563A1 (de)
MX (1) MX9203444A (de)
NL (1) NL300103I2 (de)
NO (2) NO304774B1 (de)
NZ (1) NZ243288A (de)
PL (3) PL169392B1 (de)
PT (1) PT100620B (de)
RU (1) RU2137474C1 (de)
SA (1) SA92130141B1 (de)
SG (1) SG47877A1 (de)
SI (1) SI9200125B (de)
SK (3) SK280906B6 (de)
TW (1) TW214544B (de)
UA (1) UA41254C2 (de)
WO (1) WO1993000086A1 (de)
ZA (1) ZA924658B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226566D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226530D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5616603A (en) * 1995-05-26 1997-04-01 Smithkline Beecham Plc Enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5618948A (en) * 1995-05-26 1997-04-08 Smithkline Beecham P.L.C. Process for preparing an enantiomer of a carbazole derivative
CA2179678A1 (en) * 1995-06-23 1996-12-24 Michael Edward Flaugh 6-substituted-1,2,3,4-tetrahydro-9h-carbazoles and 7-substituted-10h-cyclohepta¬7,6-b| indoles
US5917054A (en) * 1995-07-18 1999-06-29 Smithkline Beecham P.L.C. Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9723061D0 (en) * 1997-10-31 1998-01-07 Vanguard Medica Ltd Medicaments
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
GB9808069D0 (en) * 1998-04-16 1998-06-17 Vanguard Medica Ltd Novel processes
GB9817911D0 (en) * 1998-08-17 1998-10-14 Vanguard Medica Ltd New use
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
BR0312175A (pt) 2002-06-21 2005-04-05 Suven Life Sciences Ltd Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso
CN100378108C (zh) 2002-06-21 2008-04-02 苏文生命科学有限公司 对血清素受体具有亲和力、可用作治疗剂的新型四环芳基磺酰吲哚、其制备方法及其药物组合物
PT1567492E (pt) 2002-11-28 2013-07-22 Suven Life Sciences Ltd N-arilsulfonil-3-aminoalcoxi-indóis
EP1581492B1 (de) 2002-11-28 2008-07-16 Suven Life Sciences Limited N-arylsulfonyl-2-substituierte indole mit affinität zum serotonin rezeptor, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
WO2004055026A1 (en) 2002-12-18 2004-07-01 Suven Life Sciences Limited Tetracyclic 3-substituted indoles having serotonin receptor affinity
CA2658986C (en) * 2006-08-07 2014-11-25 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
EP2813144A1 (de) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgetische Zusammensetzungen enthaltend ein Antihistamin
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20090069399A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched frovatriptan
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US10098674B2 (en) 2009-10-22 2018-10-16 Nuvasive, Inc. System and method for posterior cervical fusion
US9204906B2 (en) 2009-10-22 2015-12-08 Nuvasive, Inc. Posterior cervical fusion system and techniques
WO2013016223A2 (en) 2011-07-22 2013-01-31 The University Of Chicago Treatments for migraine and related disorders
AU2013361337A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions
EP2816030A1 (de) 2013-06-20 2014-12-24 Duke Chem, S. A. Verfahren zur Herstellung von Frovatriptan und dessen Enantiomer
GB201312768D0 (en) 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
EP3423041A4 (de) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
EP3766483A1 (de) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispergierbare pulverzusammensetzung mit einem triptan

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642816A (en) * 1967-08-10 1972-02-15 Sterling Drug Inc 3-acetamido-1 2 3 4-tetrahydrocarbazole
US4062864A (en) * 1968-01-24 1977-12-13 Sterling Drug Inc. 3-Hydroxy carbazole derivatives
US3959309A (en) * 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US3592824A (en) * 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
US4172834A (en) * 1971-08-16 1979-10-30 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
BE787537A (fr) * 1971-08-16 1973-02-14 Sterling Drug Inc Tetrahydrocarbazoles
US4257952A (en) * 1977-06-06 1981-03-24 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
US4254134A (en) * 1978-03-17 1981-03-03 Endo Laboratories, Inc. Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate

Also Published As

Publication number Publication date
NO934800L (no) 1993-12-23
ZA924658B (en) 1993-12-24
AP9200403A0 (en) 1992-07-31
AU1977592A (en) 1993-01-25
GB9113802D0 (en) 1991-08-14
IL117104A (en) 1997-09-30
MA22563A1 (fr) 1992-12-31
DE10299042I1 (de) 2003-02-20
UA41254C2 (uk) 2001-09-17
IL117105A (en) 1998-01-04
NL300103I2 (nl) 2003-02-03
CA2113726C (en) 2008-02-19
CN1069726A (zh) 1993-03-10
FI103967B1 (fi) 1999-10-29
EP0591280A1 (de) 1994-04-13
PT100620A (pt) 1993-09-30
US5464864A (en) 1995-11-07
SI9200125A (en) 1992-12-31
PL171034B1 (en) 1997-02-28
NO304774B1 (no) 1999-02-15
NL300103I1 (nl) 2002-12-02
RU2137474C1 (ru) 1999-09-20
NO2005011I2 (no) 2008-02-11
CZ282083B6 (cs) 1997-05-14
CZ150696A3 (en) 1997-06-11
IE922062A1 (en) 1992-12-30
BR1100460A (pt) 2000-07-18
CZ282061B6 (cs) 1997-05-14
BR9206237A (pt) 1995-04-11
NO2005011I1 (no) 2005-05-18
AU652842B2 (en) 1994-09-08
EP0591280B1 (de) 1998-09-09
MX9203444A (es) 1993-12-01
SK280905B6 (sk) 2000-09-12
CN1034072C (zh) 1997-02-19
ATE170746T1 (de) 1998-09-15
NO934800D0 (no) 1993-12-23
US5637611A (en) 1997-06-10
DE10299042I2 (de) 2005-02-03
SA92130141B1 (ar) 2005-12-18
WO1993000086A1 (en) 1993-01-07
SI9200125B (en) 2001-12-31
HUT68961A (en) 1995-08-28
PT100620B (pt) 1999-01-29
CA2113726A1 (en) 1993-01-07
PL169392B1 (pl) 1996-07-31
CZ150596A3 (en) 1997-05-14
IL102322A (en) 1997-09-30
DE69226953T2 (de) 1999-05-12
SK280906B6 (sk) 2000-09-12
TW214544B (de) 1993-10-11
HK1014669A1 (en) 1999-09-30
SK131993A3 (en) 1994-06-08
SK280907B6 (sk) 2000-09-12
PL169410B1 (pl) 1996-07-31
CZ282327B6 (cs) 1997-06-11
NZ243288A (en) 1994-09-27
KR100251571B1 (ko) 2000-07-01
JP3261502B2 (ja) 2002-03-04
IL117105A0 (en) 1996-06-18
FI935842A0 (fi) 1993-12-23
FI935842A (fi) 1993-12-23
IL102322A0 (en) 1993-01-14
JPH06508827A (ja) 1994-10-06
DE69226953D1 (de) 1998-10-15
HU218907B (hu) 2000-12-28
CZ286193A3 (en) 1994-07-13
SG47877A1 (en) 1998-04-17
LU90939I2 (fr) 2002-09-24
FI103967B (fi) 1999-10-29
IL117104A0 (en) 1996-06-18
AP344A (en) 1994-07-05

Similar Documents

Publication Publication Date Title
DK0591280T3 (da) Anvendelse af tetrahydrocarbazolderivater som 5HT1-receptoragonister
DK0516349T3 (da) 2-hydroxy-2-phenylethylamin-derivater som beta-3-adrenoceptoragonister
KR950700906A (ko) 5-ht1 작동약으로서의 인돌 유도체(indole derivatives as 5-ht1 agonists)
DK0393936T3 (da) 3-substituerede 2-oxindolderivater som antiinflammatoriske midler
DK0856001T3 (da) Pyrimidinderivater som 5-HT2C-receptor-antagonister
NO943348L (no) Kondenserte indolderivater som 5HT4-reseptorantagonister
FI970310A0 (fi) 4-indolijohdannaiset serotoniinin vaikuttaja- ja vastavaikuttaja-aineina
FI944805A (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina
UY24555A1 (es) Nuevos compuestos
FI940574A (fi) Bentseenisulfonamidijohdannaiset herbisideinä
DK0696194T3 (da) Anvendelse af indolderivater som 5HT1-antagonister
FI962969A (fi) Indolijohdannaisia 5-HT1:n agonisteina
FI961628A (fi) Indolijohdannaisia NMDA-antagonisteina
DK0453915T3 (da) Anvendelse af N-alkyl-lactamer som krystallisationsinhibitorer
FI940192A0 (fi) 2-(4-hydroksipiperidino)-1-alkonolijohdannaisia verettömyyden vastaisina aineina
DK0769293T3 (da) Anvendelse af mindst en beta-adrenerg agonist som substans P-antagonist
DK0391171T3 (da) Anvendelse af di-styryl-phenyl-triglycolether som krystallisationsinhibitor
FI951798A0 (fi) Bentsofuraanijohdannaiset 5-HT1-kaltaisina reseptoriantagonisteina
AR005008A1 (es) Compuestos benzotiazolona etanaminas, procedimiento e intermediarios para su preparacion y su uso en la preparacion de medicamentos
FI941136A0 (fi) Kamferin piperatsinyyli(sulfonyyli)amidijohdannaiset oksitosiiniantagonisteina
DK80990D0 (da) Sulfonylderivater af thien-triazol-diazepin
DE69320653D1 (de) Tetrahydrocarbazolderivate als 5-ht1-ähnliche agonisten
FI943119A (fi) Heterosyklisellä renkaalla substituoituja bentsyyliamiinijohdannaisia retrovirusvastaisina yhdisteinä
ES2164168T3 (es) Antagonistas de receptores de fibrinogeno que tienen residuos de beta-aminoacido sustituidos y composiciones farmaceuticas que comprenden los mismos.
MX9206075A (es) Nuevos compuestos antagonistas del receptor 5-hidroxitriptamina y composiciones farmaceuticas que los contienen